FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022334458> ?p ?o ?g. }

• W2022334458 endingPage "1031" @default.
• W2022334458 startingPage "1022" @default.
• W2022334458 abstract "Abstract Background: During long-term therapy with strong opioids (step III opioids according to the World Health Organization [WHO] analgesic ladder), dose increases are often necessary because of deterioration of the primary disease or development of tolerance. Objective: The purpose of this study was to compare changes in dosages of transdermal (TD) fentanyl and TD buprenorphine in patients with cancer and non-cancer pain. Methods: In a retrospective study, patients with cancer and noncancer pain being treated with TD fentanyl or TD buprenorphine for at least 3 months between January 2001 and December 2003 were identified from the IMS Disease Analyzer-mediplus database, which contains all patient-related data documented from 400 medical practices in Germany. The indications for treatment were defined according to the International Classification of Diseases, 10th Revision, and included neoplasm (cancer groups), and osteoarthritis, low back pain, and osteoporosis (noncancer groups). The cohort pa tients were considered to have comparable pain intensity because they had received similar analgesic premedication classified according to stepsI to III of the WHO analgesic ladder (cohort groups). The mean prescribed daily doses on first and last prescription were document ed, and the mean percentile increases were calculated over the whole treatment duration and per day. Additionally, the mean percentile intraindividual increases (on a per-patient basis) were estimated. Results: The cohort groups consisted of 448 patients with noncancer pain and 446 patients with cancer pain (552 women and 342 men; mean age, 74 years; range, 25–101 years). The mean percentile increases in dosages over the whole treatment duration and adjusted per day were significantly higher in patients taking TD fentanyl (P < 0.05). Differences were even greater for the mean percentile intraindividual increases per day, which totaled 0.42%and 0.17% for cancer patients taking TD fentanyl and TD buprenorphine, respectively; corresponding values were 0.25% and 0.09%in noncancer patients (P < 0.001). Conclusions: This retrospective analysis showed a significantly higher increase in the mean daily doses of TD fentanyl as compared with TD buprenorphine. The results must be verified in prospective, randomized clinical studies. Abstract During long-term therapy with strong opioids (step III opioids according to the World Health Organization [WHO] analgesic ladder), dose increases are often necessary because of deterioration of the primary disease or development of tolerance. The purpose of this study was to compare changes in dosages of transdermal (TD) fentanyl and TD buprenorphine in patients with cancer and non-cancer pain. In a retrospective study, patients with cancer and noncancer pain being treated with TD fentanyl or TD buprenorphine for at least 3 months between January 2001 and December 2003 were identified from the IMS Disease Analyzer-mediplus database, which contains all patient-related data documented from 400 medical practices in Germany. The indications for treatment were defined according to the International Classification of Diseases, 10th Revision, and included neoplasm (cancer groups), and osteoarthritis, low back pain, and osteoporosis (noncancer groups). The cohort pa tients were considered to have comparable pain intensity because they had received similar analgesic premedication classified according to stepsI to III of the WHO analgesic ladder (cohort groups). The mean prescribed daily doses on first and last prescription were document ed, and the mean percentile increases were calculated over the whole treatment duration and per day. Additionally, the mean percentile intraindividual increases (on a per-patient basis) were estimated. The cohort groups consisted of 448 patients with noncancer pain and 446 patients with cancer pain (552 women and 342 men; mean age, 74 years; range, 25–101 years). The mean percentile increases in dosages over the whole treatment duration and adjusted per day were significantly higher in patients taking TD fentanyl (P < 0.05). Differences were even greater for the mean percentile intraindividual increases per day, which totaled 0.42%and 0.17% for cancer patients taking TD fentanyl and TD buprenorphine, respectively; corresponding values were 0.25% and 0.09%in noncancer patients (P < 0.001). This retrospective analysis showed a significantly higher increase in the mean daily doses of TD fentanyl as compared with TD buprenorphine. The results must be verified in prospective, randomized clinical studies." @default.
• W2022334458 created "2016-06-24" @default.
• W2022334458 creator A5062818266 @default.
• W2022334458 creator A5069701113 @default.
• W2022334458 creator A5069831675 @default.
• W2022334458 date "2005-07-01" @default.
• W2022334458 modified "2023-09-30" @default.
• W2022334458 title "Changes in the Prescribed Daily Doses of Transdermal Fentanyl and Transdermal Buprenorphine During Treatment of Patients with Cancer and Noncancer Pain in Germany: Results of a Retrospective Cohort Study" @default.
• W2022334458 cites W1935575719 @default.
• W2022334458 cites W1964222471 @default.
• W2022334458 cites W1982422239 @default.
• W2022334458 cites W1988133998 @default.
• W2022334458 cites W2004241500 @default.
• W2022334458 cites W2017424116 @default.
• W2022334458 cites W2019755330 @default.
• W2022334458 cites W2022974422 @default.
• W2022334458 cites W2030659020 @default.
• W2022334458 cites W2032231612 @default.
• W2022334458 cites W2035899311 @default.
• W2022334458 cites W2039443925 @default.
• W2022334458 cites W2061463537 @default.
• W2022334458 cites W2063348767 @default.
• W2022334458 cites W2068619163 @default.
• W2022334458 cites W2083064925 @default.
• W2022334458 cites W2088359192 @default.
• W2022334458 cites W2095248985 @default.
• W2022334458 cites W2100514946 @default.
• W2022334458 cites W2102487760 @default.
• W2022334458 cites W2117950925 @default.
• W2022334458 cites W2155354147 @default.
• W2022334458 cites W2887714295 @default.
• W2022334458 doi "https://doi.org/10.1016/j.clinthera.2005.06.024" @default.
• W2022334458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16154481" @default.
• W2022334458 hasPublicationYear "2005" @default.
• W2022334458 type Work @default.
• W2022334458 sameAs 2022334458 @default.
• W2022334458 citedByCount "30" @default.
• W2022334458 countsByYear W20223344582012 @default.
• W2022334458 countsByYear W20223344582013 @default.
• W2022334458 countsByYear W20223344582014 @default.
• W2022334458 countsByYear W20223344582015 @default.
• W2022334458 countsByYear W20223344582016 @default.
• W2022334458 countsByYear W20223344582017 @default.
• W2022334458 countsByYear W20223344582020 @default.
• W2022334458 countsByYear W20223344582021 @default.
• W2022334458 countsByYear W20223344582022 @default.
• W2022334458 countsByYear W20223344582023 @default.
• W2022334458 crossrefType "journal-article" @default.
• W2022334458 hasAuthorship W2022334458A5062818266 @default.
• W2022334458 hasAuthorship W2022334458A5069701113 @default.
• W2022334458 hasAuthorship W2022334458A5069831675 @default.
• W2022334458 hasConcept C121608353 @default.
• W2022334458 hasConcept C126322002 @default.
• W2022334458 hasConcept C162156334 @default.
• W2022334458 hasConcept C167135981 @default.
• W2022334458 hasConcept C170493617 @default.
• W2022334458 hasConcept C2778904085 @default.
• W2022334458 hasConcept C2778949969 @default.
• W2022334458 hasConcept C2780820201 @default.
• W2022334458 hasConcept C2781063702 @default.
• W2022334458 hasConcept C2781072394 @default.
• W2022334458 hasConcept C42219234 @default.
• W2022334458 hasConcept C71924100 @default.
• W2022334458 hasConcept C72563966 @default.
• W2022334458 hasConceptScore W2022334458C121608353 @default.
• W2022334458 hasConceptScore W2022334458C126322002 @default.
• W2022334458 hasConceptScore W2022334458C162156334 @default.
• W2022334458 hasConceptScore W2022334458C167135981 @default.
• W2022334458 hasConceptScore W2022334458C170493617 @default.
• W2022334458 hasConceptScore W2022334458C2778904085 @default.
• W2022334458 hasConceptScore W2022334458C2778949969 @default.
• W2022334458 hasConceptScore W2022334458C2780820201 @default.
• W2022334458 hasConceptScore W2022334458C2781063702 @default.
• W2022334458 hasConceptScore W2022334458C2781072394 @default.
• W2022334458 hasConceptScore W2022334458C42219234 @default.
• W2022334458 hasConceptScore W2022334458C71924100 @default.
• W2022334458 hasConceptScore W2022334458C72563966 @default.
• W2022334458 hasIssue "7" @default.
• W2022334458 hasLocation W20223344581 @default.
• W2022334458 hasLocation W20223344582 @default.
• W2022334458 hasOpenAccess W2022334458 @default.
• W2022334458 hasPrimaryLocation W20223344581 @default.
• W2022334458 hasRelatedWork W1979759405 @default.
• W2022334458 hasRelatedWork W1982468213 @default.
• W2022334458 hasRelatedWork W2061987770 @default.
• W2022334458 hasRelatedWork W2078561893 @default.
• W2022334458 hasRelatedWork W2163224481 @default.
• W2022334458 hasRelatedWork W2396983867 @default.
• W2022334458 hasRelatedWork W2411683763 @default.
• W2022334458 hasRelatedWork W2413873365 @default.
• W2022334458 hasRelatedWork W2421536329 @default.
• W2022334458 hasRelatedWork W2426466406 @default.
• W2022334458 hasVolume "27" @default.
• W2022334458 isParatext "false" @default.
• W2022334458 isRetracted "false" @default.
• W2022334458 magId "2022334458" @default.
• W2022334458 workType "article" @default.